Mutations in Specific Codons of the KRAS Oncogene are Associated with Variable Resistance to Neoadjuvant Chemoradiation Therapy in Patients with Rectal Adenocarcinoma

Identification of a Biomarker Profile Associated With Resistance to Neoadjuvant Chemoradiation Therapy in Rectal Cancer

(2011) Julio Garcia-Aguilar et al.   ANNALS OF SURGERY

Optimal Timing of Surgery After Chemoradiation for Advanced Rectal Cancer

(2011) Julio Garcia-Aguilar et al.   ANNALS OF SURGERY

Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer

(2011) Cecily P. Vaughn et al.   GENES CHROMOSOMES & CANCER

Molecular Genetic Analysis of 103 Sporadic Colorectal Tumours in Czech Patients

(2011) Peter Vasovcak et al.   PLoS One

Activating KRAS Mutations and Overexpression of Epidermal Growth Factor Receptor as Independent Predictors in Metastatic Colorectal Cancer Patients Treated With Cetuximab

(2010) Li-Chen Yen et al.   ANNALS OF SURGERY

Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab

(2010) Wendy De Roock et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

(2010) Wendy De Roock et al.   LANCET ONCOLOGY

Implications for KRAS status and EGFR-targeted therapies in metastatic CRC

(2009) Nicola Normanno et al.   Nature Reviews Clinical Oncology

KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy

(2009) Jochen Gaedcke et al.   RADIOTHERAPY AND ONCOLOGY

KRASMutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab

(2008) Astrid Lièvre et al.   JOURNAL OF CLINICAL ONCOLOGY